VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric Study

• Автори: Jocelyn Gal (Автор), Gérard Milano (Автор), Patrick Brest (Автор), Nathalie Ebran (Автор), Julia Gilhodes (Автор), Laurence Llorca (Автор), Coraline Dubot (Автор), Gilles Romieu (Автор), Isabelle Desmoulins (Автор), Etienne Brain (Автор), Anthony Goncalves (Автор), Jean-Marc Ferrero (Автор), Paul-Henri Cottu (Автор), Marc Debled (Автор), Olivier Tredan (Автор), Emmanuel Chamorey (Автор), Marco Carlo Merlano (Автор), Jérôme Lemonnier (Автор), Marie-Christine E (Автор), Jean-Yves Pierga (Автор)
• Формат: Книга
• Опубліковано: MDPI AG, 2020-11-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and al...